anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Impairments after status epilepticus have generally been assessed by physicians, using generic scales. Patient-reported outcomes (PROs) directly reflect each patient's experience and are therefore recommended to improve patient-centered care. The objective of this systematic review was to compile the available information on patient-reported outcomes of adults after status epilepticus. We used Medical Subject Headings terms to search PubMed, Embase, and the Cochrane Library from database inception to February 2023. We excluded reviews, case reports, abstract-only reports, editorials, and publications in languages other than English or French. Studies reporting PROs in adults after SE were eligible. Bias in included studies was assessed using the Newcastle-Ottawa Scale (NOS). Given the heterogeneity in assessment tools and outcomes, most of the results are presented separately for each included study. Only three studies met our criteria. All used an observational cohort design. Two were retrospective and one prospective. Of the 141 patients (76 males and 65 females, mean age 43-63 years), 105 (74.4 %) had a history of epilepsy before status epilepticus. The studies used four epilepsy-specific and five generic tools to assess five patient-reported outcomes: quality of life (n = 141), mental health (depression, n = 81, or anxiety, n = 49), physical health including fatigue (n = 130), return to work (n = 49), and side effects of antiepileptic drugs (n = 81). A single study (n = 81) was of good methodological quality. Health-related quality of life (HRQOL) and mental health were the most extensively studied outcomes, and both were impaired. HRQOL scores ranged from 41.7 ± 11.5 to 48.3 ± 24.5. The prevalence of depression and anxiety varied from 30 % to 36 %, and from 22 % to 62 %, respectively. However, data were not collected before the status epilepticus episode, and the possible impact of this last on the outcomes cannot therefore be assessed. Information on PROs of adults after status epilepticus is extremely scant. Patient-reported outcomes should be collected more widely in adults after status epilepticus.
Systemic therapies, the ultimate strategies for patients with advanced hepatocellular carcinoma (HCC), are suffering from serious clinical challenges, such as the occurrence and development of drug resistance. Treatment resistance aggravates tumor progression partly by inducing tumor metastasis. Regorafenib-resistant HCC cells exhibit a highly striking metastatic phenotype, but the detailed mechanisms underlying these aggressive behaviors remain elusive. Here, we conduct transcriptome sequencing analysis to identify COL5A2 as a crucial driver of the metastatic characteristics of regorafenib-resistant HCC cells. COL5A2 is aberrantly highly expressed in resistant cells, and its genetic depletion significantly suppresses proliferation, migration, invasion, vasculogenic mimicry (VM) formation and lung metastasis in vitro and in vivo, concomitant with the downregulation of VE-cadherin, EphA2, Twist1, p-p38 and p-STAT3 expressions. LIFR is confirmed to be an essential downstream molecule of COL5A2, and its expression is observably elevated by COL5A2 depletion. Ectopic overexpression of LIFR drastically attenuates the proliferation, migration, invasion and VM of regorafenib-resistant cells and represses the expressions of VM-related molecules and the activation of p38/STAT3 signaling pathway. Interestingly, rescue experiments show that the inhibition of the above aggressive features of resistant cells by COL5A2 loss is clearly alleviated by silencing of LIFR. Collectively, our results reveal that COL5A2 promotes the ability of regorafenib-resistant HCC cells to acquire a metastatic phenotype by attenuating LIFR expression and suggest that therapeutic regimens targeting the COL5A2/LIFR axis may be beneficial for HCC patients with therapeutic resistance.
A process and apparatus are provided for making hollow macrospherical particles. The particles themselves are particularly adapted for use as anti-perspirants. The particles have a diameter between about 10 and 74 microns, preferably predominating between 15 and 44 microns, and a greater than unit density. As such, they are not subject to deep lung penetration. The process for producing the particles comprises providing a solution containing the materials from which the particles are made, diffusing the solution through small pores by centrifugal force such that the resulting hollow particles have a diameter greater than the pore diameter, and drying the solution droplets in a stream of heated air. The apparatus for producing the macrospherical particles comprises a centrifugal atomizer having a porous sintered metal filter ring which is rotated inside a spray drying chamber. The filter is treated to produce hollow macrospheres having substantially smooth outer walls of such thickness that they can withstand normal shipment and handling without significant fragmentation.
Risk Summary

No studies have been conducted with the use of DUEXIS in lactating women. Limited data from published literature report famotidine is present in human milk in low amounts. Published literature also reports the presence of ibuprofen in human milk in low amounts. No information is available on the effects of famotidine or ibuprofen on milk production or on a breastfed infant. Famotidine is present in the milk of lactating rats (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUEXIS and any potential adverse effects on the breastfed infant from DUEXIS or from the underlying maternal condition.

Data

Transient growth depression was observed in young rats suckling from mothers treated with maternotoxic doses of at least 300 times the usual human dose of famotidine.
All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer \[18F\](+/-)NOS.
Polyploid wheats include a group of tetraploids known as Timopheevii (AuAuGG), which are represented by two subspecies: Triticum timopheevii ssp. timopheevii (cultivated) and Triticum timopheevii ssp. araraticum (wild). The combined use of electrophoretic (SDS-PAGE) and chromatographic (RP-HPLC) techniques carried out on high-molecular-weight glutenin subunits (HMW-GSs) permitted the association of different x- and y-type subunits to the A and G genomes and the assessment of allelic variation present at corresponding loci. The results also revealed that in both subspecies, accessions are present that possess expressed y-type subunits at the Glu-A1 locus. Genes corresponding to these subunits were amplified and amplicons corresponding to x- and y-type genes associated with the A genome were detected in all accessions, including those without expressed x- and y-type subunits. The comparison with genes of polyploid wheats confirmed the structural characteristics of typical y-type genes, with the presence of seven cysteine residues and with hexapeptide and nonapeptide repeat motifs. The identification of wild and cultivated T. timopheevii with both x- and y-type glutenin subunits at the Glu-A1 and Glu-G1 loci represents a useful source for the modification of the allelic composition of HMW-GSs in cultivated wheats with the ultimate objective of improving technological properties.
PROBLEM TO BE SOLVED: To provide a new and safe cosmetic composition. SOLUTION: A melanogenesis suppressing agent, an active oxygen scavenger, a lipid peroxide formation suppressing agent, an antiallergic agent, a histamine isolation suppressing agent, an anticomplement activation agent and a cosmetic composition are produced by including an extract of one or more vegetables selected from Crataegus oxyacantha and Potentilla tormentilla. The agents have melanogenesis suppressing action, active oxygen scavenging action, lipid peroxide formation suppressing action, antiallergic action, histamine isolation suppressing action and anticomplement activation action as well as cosmetic action to decrease blotches and freckles and give fair skin. These agents are effective also for the improvement of dermatic inflammation diseases (e.g. rubefaction, edema and eczema), roughened skin and xeroderma and the impartment of the skin with gloss and springiness.  The technique can be applied to foods and drinks in general.
The present invention relates to hypoglycemic health-care tea and a production method thereof, which belongs to the field of beverages. The hypoglycemic health-care tea is prepared from 1.5 to 2.5 of tea, 1.5 to 2.5 of trichosanthes root and 0.5 to 1.2 of pueraria root. A tea beverage prepared from pure natural Chinese herbal medicines is provided by combining the hypoglycemic effect, the health-care effect and a tea beverage carrier. The product of the present invention is comfortable in the mouth feeling and has fragrant odor. The product of the present invention has the maximal advantage of no side effect, and has obvious effects of health care and adjutant therapy. The hypoglycemic health-care tea can be served as a beverage for long-term drinking.
The standard (comparison group) package will consist of Canada's family guide to physical activity guidelines recommending 60 minutes of activity a day in bouts as short as five to ten minutes for children and a breakdown of ways for the family to achieve this physical activity (structured, unstructured, endurance, strength, activities, less than 60 minutes of sustained sedentary activity, reduce screen viewing by 30 min per day) commensurate with this guide. This will include the new insert by CSEP. The guide also contains arguments and information about the benefits of physical activity.
BACKGROUND: Interventions to prevent excessive gestational weight gain (GWG) have had a limited impact on maternal and infant outcomes. Dietary fiber is a nutrient with benefits that counters many of the metabolic and inflammatory changes that occur during pregnancy. We will determine if a high dietary fiber (HFib) intervention provides benefit to maternal and infant outcomes.
METHODS AND DESIGN: Pregnant women will be enrolled in an 18-week intervention and randomized in groups of 6-10 women/group into the intervention or control group. Weekly lessons will include information on high-dietary fiber foods and behavior change strategies. Women in the intervention group will be given daily snacks high in dietary fiber (10-12 g/day) to facilitate increasing dietary fiber intake. The primary aim will assess between-group differences for the change in maternal weight, dietary fiber intake, dietary quality, and body composition during pregnancy and up to two months post-partum. The secondary aim will assess between-group differences for the change in maternal weight, dietary fiber intake, and dietary quality from two months to one year post-partum and infant body composition from birth to one-year-old.
DISCUSSION: Effective and simple intervention strategies to improve maternal and offspring outcomes are lacking. Changes during the perinatal period are related to the risk of disease development in the mother and offspring. However, it is unknown which changes can be successfully targeted to have a meaningful impact. We will test the effect of an intervention designed to counter many of the metabolic and inflammatory changes that occur during pregnancy.
ETHICS AND DISSEMINATION: The University of Kansas Medical Center Institutional Review Board (IRB) approved the study protocol (STUDY00145397). The results of the trial will be disseminated at conferences and in peer reviewed publications.
TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT04868110.
The investigators will measure pain severity, pain interference, and fear of falling at baseline, mid-point (3-month), and post-intervention (6-month), as well as rate of falls during the intervention (0- to 6-month) and the 6-month follow-up period (month 6 to month 12) in 266 older adults (Tai Chi: N=133, and light physical exercise control: N=133). In addition, they will measure pain-related biomarkers, cognition, single-task and dual-task gait function, free-living physical activity, and sleep at baseline, mid-point, and post-intervention. The primary aims are: 1. to examine the effects of Tai Chi on pain symptoms in older adults with multisite pain. It is hypothesized that older adults in the Tai Chi intervention will have less pain, measured as pain severity and interference, than those in the light physical exercise control group; 2. to examine the effects of Tai Chi on fear of falling and rate of falls in older adults with multisite pain. It is hypothesized that older adults in the Tai Chi intervention will have less fear of falling and fewer falls than those in the light physical exercise control group. The secondary/exploratory aims are: 3. to examine the effects of Tai Chi on pain-related biomarkers in older adults with multisite pain. It is hypothesized that Tai Chi intervention will have greater reductions in levels of pain-related biomarkers and and beta endorphin, than those in the light physical exercise control group; 4. to examine the roles of changes in pain symptoms in the change of fall rate by Tai Chi in older adults with multisite pain. It is hypothesized that the effect of Tai Chi on the reduced fall rate will be explained in part by improvements in pain symptoms in older adults with multisite pain; 5. to examine the roles of changes in cognition and cognitive motor function in the change of fall rate by Tai Chi in older adults with multisite pain. It is hypothesized that the reduced fall rate in the Tai Chi group will be mediated by changes in cognition and cognitive-motor function in older adults with multisite pain.
The invention relates to a composition containing sporopollenin. Said composition is characterised in that it is present as a solution and contains in addition to between 0.01 and 12 wt. %, preferably between 0.1 and 5 wt. % of sporopollenin, between 0.01 and 17 wt. %, preferably between 0.1 and 10 wt. % of at least one emulsifier and between 71.00 and 99.98 wt. %, preferably between 85 and 99.80 wt. % of at least one hydrophilic solvent. The invention also relates to the use of said composition for cosmetic and pharmaceutical purposes, as a chelating agent and as a food supplement.
Placebo Transcranial Magnetic stimulation delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
All patients were treated with 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
Hepatic ischemia-reperfusion injury (HIRI) elicits an immune-inflammatory response that may result in hepatocyte necrosis and apoptosis, ultimately culminating in postoperative hepatic dysfunction and hepatic failure. The precise mechanisms governing the pathophysiology of HIRI remain incompletely understood, necessitating further investigation into key molecules and pathways implicated in disease progression to guide drug discovery and potential therapeutic interventions. Gene microarray data was downloaded from the GEO expression profile database. Integrated bioinformatic analyses were performed to identify HIRI signature genes, which were subsequently validated for expression levels and diagnostic efficacy. Finally, the gene expression was verified in an experimental HIRI model and the effect of anti-IL17A antibody intervention in three time points (including pre-ischemic, post-ischemic, and at 1 h of reperfusion) on HIRI and the expression of these genes was investigated. Bioinformatic analyses of the screened characterized genes revealed that inflammation, immune response, and cell death modulation were significantly associated with HIRI pathophysiology. CCL2, BTG2, GADD45A, FOS, CXCL10, TNFRSF12A, and IL-17 pathway were identified as key components involved in the HIRI. Serum and liver IL-17A expression were significantly upregulated during the initial phase of HIRI. Pretreatment with anti-IL-17A antibody effectively alleviated the damage of liver tissue, suppressed inflammatory factors, and serum transaminase levels, and downregulated the mRNA expression of CCL2, GADD45A, FOS, CXCL10, and TNFRSF12A. Injection of anti-IL17A antibody after ischemia and at 1 h of reperfusion failed to demonstrate anti-inflammatory and attenuating HIRI benefits relative to earlier intervention. Our study reveals that the IL-17 pathway and related genes may be involved in the proinflammatory mechanism of HIRI, which may provide a new perspective and theoretical basis for the prevention and treatment of HIRI.
<P>PROBLEM TO BE SOLVED: To provide an external purposeful hair-growing agent having no adverse effect and used by directly applying it on a local place (head skin).  <P>SOLUTION: The various hair-growing agents such as a lotion type and cream type are prepared by containing cyproterone acetate as an active ingredient. By applying the lotion type external hair-growing agent containing 0.02-0.1 wt. % cyproterone acetate once daily, or applying the cream type external hair-growing agent containing 0.4-1.2 wt. % cyproterone acetate, and preferably using an adrenocortical hormone jointly once in 3-5 days, a significant hair-growing acceleration effect is obtained without showing any adverse effect.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
FIELD: medicine, particularly, stomatology. SUBSTANCE: invention deals with means for oral cavity and teeth care. Proposed tooth paste contains an abrasive and adsorbing component - that is activated carbon, common salt with microadditives of silver ions, and glycerine. The tooth paste is nontoxic and may include lauryl sarcosinate. Ingredients are taken in determined ratio. EFFECT: increased bactericidal action. 2 cl
TFE3-rearranged renal cell cancer (tRCC) is a rare form of RCC that involves chromosomal translocation of the Xp11.2 TFE3 gene. Despite its early onset and poor prognosis, the molecular mechanisms of the pathogenesis of tRCC remain elusive. This study aimed to identify novel therapeutic targets for patients with primary and recurrent tRCC. We collected 19 TFE3-positive RCC tissues that were diagnosed by immunohistochemistry and subjected them to genetic characterization to examine their genomic and transcriptomic features. Tumor-specific signatures were extracted using whole exome sequencing (WES) and RNA sequencing (RNA-seq) data, and the functional consequences were analyzed in a cell line with TFE3 translocation. Both a low burden of somatic single nucleotide variants (SNVs) and a positive correlation between the number of somatic variants and age of onset were observed. Transcriptome analysis revealed that four samples (21.1%) lacked the expected fusion event and clustered with the genomic profiles of clear cell RCC (ccRCC) tissues. The fusion event also demonstrated an enrichment of upregulated genes associated with mitochondrial respiration compared with ccRCC expression profiles. Comparison of the RNA expression profile with the TFE3 ChIP-seq pattern data indicated that PPARGC1A is a metabolic regulator of the oncogenic process. Cell proliferation was reduced when PPARGC1A and its related metabolic pathways were repressed by its inhibitor SR-18292. In conclusion, we demonstrate that PPARGC1A-mediated mitochondrial respiration can be considered a potential therapeutic target in tRCC. This study identifies an uncharacterized genetic profile of an RCC subtype with unique clinical features and provides therapeutic options specific to tRCC.
An MCM system is provided for multiple audiences or programs for a system and method of handling participants. The MCM eliminates unnecessary human decision making by using measurements of key data to algorithmically determine future actions. The individual systems are programmed to handle recommendations of content (content management) and to produce workflow, reports, and analytics based on the core content of a program. The MCM system is used to manage participant behaviors, for example, those involved in Population Health Management, Care Management, Managed Care, treatment/care/behavior planning, and workforce development. The MCM provides recommendations and predictions about patients from a specific healthcare plan or patients sharing similar conditions. This system has recurring measurements and actionable outcomes that allow participants to meet their goals incrementally over established clinical timespans.
The present invention discloses a medicine for treating cough. The medicine is a Chinese patent medicine prepared from Premna microphylla Turez, solomonseal rhizome, baiwei ginseng, platycodon root, saxifraga, loquat leaf, ephedra, white mulberry root bark and opium poppy shell as main raw materials through a conventional preparation technology. The present invention provides a medicine prepared according to a miao medicine theory. Chinese medicinal herbs frequently sawn in local places are used as raw materials, and the cost is low. The medicine has the functions for invigorating vital energy, nourishing yin, moistening the lung and stopping cough, has the characteristics of simple preparation, lower cost and good therapeutic effect, and can be used for treating diseases such as cough, dry throat, etc. which are caused by cold, acute bronchitis and chronic bronchitis.
The invention relates to a qingyan granule. The qingyan granule is composed of extractives of the following raw materials and a sweetening agent. The raw materials comprise, by weight, 20-30 parts of radix platycodonis, 15-25 parts of radix ophiopogonis, 18-26 parts of radix glehniae, 10-20 parts of liquorice, 5-15 parts of corn mint, 5-15 parts of semen coicis and 10-20 parts of herba houttuyniae. The weight part of the sweetening agent is 0-0.3. The qingyan granule is reasonable in formula and rich in bioactive substances such as saponin and polysaccharide, the animal experimental result shows that rat voix pedis swelling can be obviously lightened, and the human experimental result shows that pharyngeal mucosal hyperemia and mucosa edema can be obviously lightened. The qingyan granule has the advantages that the health care effect of clearing heat from the throat is achieved, the function is lasting, the source of the raw materials is wide, the quality is reliable and the qingyan granule is affordable.
Aminolevulinic acid HCL 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
PCT No. PCT/JP95/00527 Sec. 371 Date Oct. 17, 1996 Sec. 102(e) Date Oct. 17, 1996 PCT Filed Mar. 22, 1995 PCT Pub. No. WO95/28961 PCT Pub. Date Nov. 2, 1995A drug for the treatment of rheumatoid arthritis, which comprises as an active ingredient a monoclonal antibody which recognizes specifically extracellular region of human VLA-2. Preferable drug for the treatment of rheumatoid arthritis comprises as an active ingredient a monoclonal antibody which recognizes specifically extracellular region of human VLA-2,  alpha  chain. The above drug for the treatment of rheumatoid arthritis can suppress swelling due to arthritis in rheumatoid arthritis with low toxicity and hence is useful for the treatment of rheumatoid arthritis.
Body-satisfied women will be recruited to engage in the assessment portion of the study only (i.e. they will be given NO intervention but are serving as a control in terms of eye-tracking assessment). Body-satisfied women will be assessed to compare their attention to weight words with body-dissatisfied women's attention to weight words. This comparison will be done with an aim of replicating the findings of Tobin (2015), to ensure that for this particular sample, body-dissatisfied women exhibit stronger attentional biases for weight words than body-satisfied women. Attention to weight words in body-satisfied women will be assessed at two time points, one week apart, to ensure there are no spurious changes in attention in body satisfied women.